Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane-Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma.

Mohammed A, Janakiram NB, Madka V, Zhang Y, Singh A, Biddick L, Li Q, Lightfoot S, Steele VE, Lubet RA, Suen CS, Miller MS, Sei S, Rao CV.

Cancer Prev Res (Phila). 2019 Sep 17. doi: 10.1158/1940-6207.CAPR-19-0312. [Epub ahead of print]

PMID:
31530543
2.

Targeting cholecystokinin-2 receptor for pancreatic cancer chemoprevention.

Mohammed A, Janakiram NB, Suen C, Stratton N, Lightfoot S, Singh A, Pathuri G, Ritchie R, Madka V, Rao CV.

Mol Carcinog. 2019 Oct;58(10):1908-1918. doi: 10.1002/mc.23084. Epub 2019 Jul 16.

PMID:
31313401
3.

Correlation of clinical data with fallopian tube specimen immune cells and tissue culture capacity.

Ramraj SK, Smith KM, Janakiram NB, Toal C, Raman A, Benbrook DM.

Tissue Cell. 2018 Jun;52:57-64. doi: 10.1016/j.tice.2018.04.001. Epub 2018 Apr 4.

4.

Development of a dietary formulation of the SHetA2 chemoprevention drug for mice.

Benbrook DM, Janakiram NB, Chandra V, Pathuri G, Madka V, Stratton NC, Masamha CP, Farnsworth CN, Garcia-Contreras L, Hatipoglu MK, Lighfoot S, Rao CV.

Invest New Drugs. 2018 Aug;36(4):561-570. doi: 10.1007/s10637-017-0550-0. Epub 2017 Dec 22.

5.

Lack of chemopreventive effects of P2X7R inhibitors against pancreatic cancer.

Mohammed A, Janakiram NB, Madka V, Pathuri G, Li Q, Ritchie R, Biddick L, Kutche H, Zhang Y, Singh A, Gali H, Lightfoot S, Steele VE, Suen CS, Rao CV.

Oncotarget. 2017 Oct 26;8(58):97822-97834. doi: 10.18632/oncotarget.22085. eCollection 2017 Nov 17.

6.

Loss of natural killer T cells promotes pancreatic cancer in LSL-KrasG12D/+ mice.

Janakiram NB, Mohammed A, Bryant T, Ritchie R, Stratton N, Jackson L, Lightfoot S, Benbrook DM, Asch AS, Lang ML, Rao CV.

Immunology. 2017 Sep;152(1):36-51. doi: 10.1111/imm.12746. Epub 2017 May 29.

7.

Immunoprevention of Pancreatic Cancer.

Rao CV, Mohammed A, Asch AS, Janakiram NB.

Curr Med Chem. 2018;25(22):2576-2584. doi: 10.2174/0929867324666170223153509. Review.

PMID:
28240168
8.

Current Challenges and Opportunities for Chemoprevention of Pancreatic Cancer.

Mohammed A, Janakiram NB, Madka V, Li M, Asch AS, Rao CV.

Curr Med Chem. 2018;25(22):2535-2544. doi: 10.2174/0929867324666170209104453. Review.

PMID:
28183260
9.

Molecular Pathways: Mucins and Drug Delivery in Cancer.

Rao CV, Janakiram NB, Mohammed A.

Clin Cancer Res. 2017 Mar 15;23(6):1373-1378. doi: 10.1158/1078-0432.CCR-16-0862. Epub 2016 Dec 30.

10.

Potentiating NK cell activity by combination of Rosuvastatin and Difluoromethylornithine for effective chemopreventive efficacy against Colon Cancer.

Janakiram NB, Mohammed A, Bryant T, Zhang Y, Brewer M, Duff A, Biddick L, Singh A, Lightfoot S, Steele VE, Rao CV.

Sci Rep. 2016 Nov 14;6:37046. doi: 10.1038/srep37046.

11.

Small-Molecule Inhibition of GCNT3 Disrupts Mucin Biosynthesis and Malignant Cellular Behaviors in Pancreatic Cancer.

Rao CV, Janakiram NB, Madka V, Kumar G, Scott EJ, Pathuri G, Bryant T, Kutche H, Zhang Y, Biddick L, Gali H, Zhao YD, Lightfoot S, Mohammed A.

Cancer Res. 2016 Apr 1;76(7):1965-74. doi: 10.1158/0008-5472.CAN-15-2820. Epub 2016 Feb 15.

12.

Prevention and treatment of cancers by immune modulating nutrients.

Janakiram NB, Mohammed A, Madka V, Kumar G, Rao CV.

Mol Nutr Food Res. 2016 Jun;60(6):1275-94. doi: 10.1002/mnfr.201500884. Epub 2016 Mar 9. Review.

13.

Systemic Chromosome Instability Resulted in Colonic Transcriptomic Changes in Metabolic, Proliferation, and Stem Cell Regulators in Sgo1-/+ Mice.

Rao CV, Sanghera S, Zhang Y, Biddick L, Reddy A, Lightfoot S, Janakiram NB, Mohammed A, Dai W, Yamada HY.

Cancer Res. 2016 Feb 1;76(3):630-42. doi: 10.1158/0008-5472.CAN-15-0940.

14.

Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.

Rao CV, Janakiram NB, Madka V, Devarkonda V, Brewer M, Biddick L, Lightfoot S, Steele VE, Mohammed A.

Oncotarget. 2015 Oct 20;6(32):33290-305. doi: 10.18632/oncotarget.5396.

15.

Molecular Targeted Intervention for Pancreatic Cancer.

Mohammed A, Janakiram NB, Pant S, Rao CV.

Cancers (Basel). 2015 Aug 10;7(3):1499-542. doi: 10.3390/cancers7030850. Review.

16.

Sea Cucumbers Metabolites as Potent Anti-Cancer Agents.

Janakiram NB, Mohammed A, Rao CV.

Mar Drugs. 2015 May 12;13(5):2909-23. doi: 10.3390/md13052909. Review.

17.

Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression.

Mohammed A, Janakiram NB, Madka V, Brewer M, Ritchie RL, Lightfoot S, Kumar G, Sadeghi M, Patlolla JM, Yamada HY, Cruz-Monserrate Z, May R, Houchen CW, Steele VE, Rao CV.

Oncotarget. 2015 Jun 20;6(17):15524-39.

18.

Improved innate immune responses by Frondanol A5, a sea cucumber extract, prevent intestinal tumorigenesis.

Janakiram NB, Mohammed A, Bryant T, Lightfoot S, Collin PD, Steele VE, Rao CV.

Cancer Prev Res (Phila). 2015 Apr;8(4):327-37. doi: 10.1158/1940-6207.CAPR-14-0380. Epub 2015 Feb 5.

19.

Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling.

Mohammed A, Janakiram NB, Madka V, Ritchie RL, Brewer M, Biddick L, Patlolla JM, Sadeghi M, Lightfoot S, Steele VE, Rao CV.

Cancer Prev Res (Phila). 2014 Dec;7(12):1198-209. doi: 10.1158/1940-6207.CAPR-14-0176. Epub 2014 Sep 23.

20.

The role of inflammation in colon cancer.

Janakiram NB, Rao CV.

Adv Exp Med Biol. 2014;816:25-52. doi: 10.1007/978-3-0348-0837-8_2. Review.

PMID:
24818718
21.

Adoptive transfer of regulatory T cells promotes intestinal tumorigenesis and is associated with decreased NK cells and IL-22 binding protein.

Janakiram NB, Mohammed A, Bryant T, Brewer M, Biddick L, Lightfoot S, Lang ML, Rao CV.

Mol Carcinog. 2015 Oct;54(10):986-98. doi: 10.1002/mc.22168. Epub 2014 May 5.

PMID:
24797894
22.

Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling.

Mohammed A, Janakiram NB, Brewer M, Ritchie RL, Marya A, Lightfoot S, Steele VE, Rao CV.

Transl Oncol. 2013 Dec 1;6(6):649-59. eCollection 2013 Dec 1.

23.

Raloxifene and antiestrogenic gonadorelin inhibits intestinal tumorigenesis by modulating immune cells and decreasing stem-like cells.

Janakiram NB, Mohammed A, Brewer M, Bryant T, Biddick L, Lightfoot S, Pathuri G, Gali H, Rao CV.

Cancer Prev Res (Phila). 2014 Mar;7(3):300-9. doi: 10.1158/1940-6207.CAPR-13-0345. Epub 2014 Jan 15.

24.

Chemopreventive efficacy of raloxifene, bexarotene, and their combination on the progression of chemically induced colon adenomas to adenocarcinomas in rats.

Janakiram NB, Mohammed A, Zhang Y, Brewer M, Bryant T, Lightfoot S, Steele VE, Rao CV.

Cancer Prev Res (Phila). 2013 Dec;6(12):1251-61. doi: 10.1158/1940-6207.CAPR-13-0249. Epub 2013 Sep 30.

25.

Chemopreventive effects of PBI-Se, a selenium-containing analog of PBIT, on AOM-induced aberrant crypt foci in F344 rats.

Janakiram NB, Mohammed A, Ravillah D, Choi CI, Zhang Y, Desai D, Amin S, Rao CV.

Oncol Rep. 2013 Aug;30(2):952-60. doi: 10.3892/or.2013.2483. Epub 2013 May 23.

PMID:
23708609
26.

Multitargeted low-dose GLAD combination chemoprevention: a novel and promising approach to combat colon carcinogenesis.

Mohammed A, Janakiram NB, Brewer M, Vedala K, Steele VE, Rao CV.

Neoplasia. 2013 May;15(5):481-90.

27.

Endogenous n-3 polyunsaturated fatty acids delay progression of pancreatic ductal adenocarcinoma in Fat-1-p48(Cre/+)-LSL-Kras(G12D/+) mice.

Mohammed A, Janakiram NB, Brewer M, Duff A, Lightfoot S, Brush RS, Anderson RE, Rao CV.

Neoplasia. 2012 Dec;14(12):1249-59.

28.

Lipoxygenase and Cyclooxygenase Pathways and Colorectal Cancer Prevention.

Rao CV, Janakiram NB, Mohammed A.

Curr Colorectal Cancer Rep. 2012 Dec;8(4):316-324.

29.

iNOS-selective inhibitors for cancer prevention: promise and progress.

Janakiram NB, Rao CV.

Future Med Chem. 2012 Nov;4(17):2193-204. doi: 10.4155/fmc.12.168. Review.

30.

Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48(Cre/+)-LSL-Kras(G12D/+) mice.

Rao CV, Mohammed A, Janakiram NB, Li Q, Ritchie RL, Lightfoot S, Vibhudutta A, Steele VE.

Neoplasia. 2012 Sep;14(9):778-87.

31.

Early detection and prevention of pancreatic cancer: use of genetically engineered mouse models and advanced imaging technologies.

Mohammed A, Janakiram NB, Lightfoot S, Gali H, Vibhudutta A, Rao CV.

Curr Med Chem. 2012;19(22):3701-13. Review.

PMID:
22680929
32.

Prophylactic vaccine approach for colon and pancreatic cancers: present and future.

Janakiram NB, Mohammed A, Bronze MS, Rao CV.

Curr Med Chem. 2012;19(22):3664-78. Review.

PMID:
22680926
33.

Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apc(Min/+) mice.

Janakiram NB, Mohammed A, Qian L, Choi CI, Steele VE, Rao CV.

Neoplasia. 2012 Feb;14(2):159-68.

34.

Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice.

Mohammed A, Qian L, Janakiram NB, Lightfoot S, Steele VE, Rao CV.

Int J Cancer. 2012 Oct 15;131(8):1951-62. doi: 10.1002/ijc.27456. Epub 2012 Mar 14.

35.

Chemoprevention of Colon Cancer by iNOS-Selective Inhibitors.

Janakiram NB, Rao CV.

For Immunopathol Dis Therap. 2012 Jan 1;3(2):155-167.

36.

Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer.

Janakiram NB, Mohammed A, Rao CV.

Cancer Metastasis Rev. 2011 Dec;30(3-4):507-23. doi: 10.1007/s10555-011-9311-2. Review.

PMID:
22015691
37.

Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention.

Mohammed A, Janakiram NB, Li Q, Choi CI, Zhang Y, Steele VE, Rao CV.

Cancer Prev Res (Phila). 2011 Dec;4(12):2015-26. doi: 10.1158/1940-6207.CAPR-11-0233. Epub 2011 Sep 1.

38.

Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/β-catenin/cyclin D1 signaling pathway in rats.

Suh N, Reddy BS, DeCastro A, Paul S, Lee HJ, Smolarek AK, So JY, Simi B, Wang CX, Janakiram NB, Steele V, Rao CV.

Cancer Prev Res (Phila). 2011 Nov;4(11):1895-902. doi: 10.1158/1940-6207.CAPR-11-0222. Epub 2011 Jul 15.

39.

Briarane diterpenes diminish COX-2 expression in human colon adenocarcinoma cells.

Joyner PM, Waters AL, Williams RB, Powell DR, Janakiram NB, Rao CV, Cichewicz RH.

J Nat Prod. 2011 Apr 25;74(4):857-61. doi: 10.1021/np100775a. Epub 2011 Mar 25.

PMID:
21438584
40.

The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model.

Mohammed A, Janakiram NB, Li Q, Madka V, Ely M, Lightfoot S, Crawford H, Steele VE, Rao CV.

Cancer Prev Res (Phila). 2010 Nov;3(11):1417-26. doi: 10.1158/1940-6207.CAPR-10-0038.

41.

Chemopreventive effects of Frondanol A5, a Cucumaria frondosa extract, against rat colon carcinogenesis and inhibition of human colon cancer cell growth.

Janakiram NB, Mohammed A, Zhang Y, Choi CI, Woodward C, Collin P, Steele VE, Rao CV.

Cancer Prev Res (Phila). 2010 Jan;3(1):82-91. doi: 10.1158/1940-6207.CAPR-09-0112.

42.

Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer.

Janakiram NB, Rao CV.

Curr Mol Med. 2009 Jun;9(5):565-79. Review.

PMID:
19601807
43.

Estrogen receptor-beta as a potential target for colon cancer prevention: chemoprevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 rats.

Janakiram NB, Steele VE, Rao CV.

Cancer Prev Res (Phila). 2009 Jan;2(1):52-9. doi: 10.1158/1940-6207.CAPR-08-0140.

44.

Chemoprevention of colon carcinogenesis by oleanolic acid and its analog in male F344 rats and modulation of COX-2 and apoptosis in human colon HT-29 cancer cells.

Janakiram NB, Indranie C, Malisetty SV, Jagan P, Steele VE, Rao CV.

Pharm Res. 2008 Sep;25(9):2151-7. doi: 10.1007/s11095-008-9582-7. Epub 2008 Apr 12.

PMID:
18408893
45.

Beta-ionone inhibits colonic aberrant crypt foci formation in rats, suppresses cell growth, and induces retinoid X receptor-alpha in human colon cancer cells.

Janakiram NB, Cooma I, Mohammed A, Steele VE, Rao CV.

Mol Cancer Ther. 2008 Jan;7(1):181-90. doi: 10.1158/1535-7163.MCT-07-0529.

46.

Molecular markers and targets for colorectal cancer prevention.

Janakiram NB, Rao CV.

Acta Pharmacol Sin. 2008 Jan;29(1):1-20. Review.

Supplemental Content

Loading ...
Support Center